Multiple myeloma, also known as myeloma, is the third most common hematologic cancer (cancer of the blood). However, compared to more frequently occurring cancers (e.g., breast, prostate, lung, and colorectal cancers), multiple myeloma is relative rare and accounts for only 1.6 percent of diagnoses each year. For 2018, the American Cancer Society estimates that 30,770 new cases of myeloma will be diagnosed in the U.S.1 Due to the less common occurrence of multiple myeloma, providers are less likely to diagnosis and treat these patients on a regular basis.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68:7-30.
ACCC has developed an educational initiative to raise awareness among cancer programs about treatment options for newly diagnosed patients with multiple myeloma who are ineligible for transplant.
The overall aim of this project is to analyze and summarize existing dispensing models and effective practices in the care of patients with multiple myeloma.
This educational initiative is aimed at improving provider communication to optimize the treatment of multiple myeloma patients in the community cancer center pre- and post-autologous stem cell transplant (ASCT).
Alexandra Howson, PHD
The Association of Community Cancer Centers (ACCC) has supported QI initiatives for many years through its Visiting Experts Program. In 2020 ACCC offered QI programs designed to optimize care for patients with multiple myeloma. Via custom workshops, multidisciplinary team members from three cancer programs appraised their own challenges and opportunities to improve care and developed QI plans that were specific, measurable, and actionable over a six-month time frame. The QI time frame included workshop participation, baseline data reporting, progress calls with ACCC, and outcomes evaluation.
Thank you to our Cancer Program Members:
Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery offers a convenient summary of recent updates in the management of this heterogeneous disease, including information on:
Plus, read how three cancer programs—a community-based comprehensive program, an academic medical center, and an NCI-designated program—are delivering multidisciplinary care to this patient population.
ACCC thanks the following member programs for their participation:
Caring for patients with acute myeloid leukemia (AML) depends on many factors and can vary as much as the patients themselves.
Three specialists in multiple myeloma care share their experiences that may help other providers and patients move smoothly through this time of transition while maintaining high quality care.
Learn how to identify key disparities in clinical trial access for patients with multiple myeloma and explore strategies that can help improve access for underserved communities. (October 21, 2020)
Effective communication with patients is key to providing optimal care to patients. Learn the most effective strategies for successful conversation with patients undergoing treatment for multiple myeloma and discover valuable resources that can help.
Expert faculty will Identify new emerging therapies in the care for multiple myeloma patients and provide examples of how to operationalize care of this patient population.
Learn how to better identify and utilize financial resources that are available for patients with multiple myeloma, and implement strategies to improve insurance verification procedures.
Causes, risk factors, and prevention vary among cancer types, and multiple myeloma presents its own unique risk factors, such as age, gender, race, and family history, among others. Learn about the various precursor conditions for multiple myeloma and how to determine the risk of developing the disease.
COVID-19 has impacted how providers are dispensing multiple myeloma medications and providing care to patients during the pandemic. Learn how to identify those effects to help mitigate them and implement strategies to improve telehealth medicine during the pandemic.
Funding & support provided by Amgen Oncology